← Ишга қайтиш
Ушбу иш иқтибос қилган ишлар
206 та иш
Иш: Advances in monitoring and therapy from minimal residual disease to CAR-T cells in multiple myeloma and precursor disorders
The Benefits and Safety of Monoclonal Antibodies: Implications for Cancer Immunotherapy
Shuguang Zhang, Wen‐Ying Chen, Jihong Zhou +5
Шарҳ мақола20257 иқтибосABIUnlocking the full potential of memory T cells in adoptive T cell therapy for hematologic malignancies
Ding-Ya Sun, Yijie Hu, Xin Li +3
Шарҳ мақола20247 иқтибосABIIdecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C. Munshi, Larry D. Anderson, Nina Shah +25
Мақола20215 иқтибосABIMultidrug resistance in cancer: role of ATP–dependent transporters
Michael M. Gottesman, Tito Fojo, Susan E. Bates
Шарҳ мақола20024 иқтибосABIHarnessing bacteria for tumor therapy: Current advances and challenges
Lina Guo, Jinsong Ding, Wenhu Zhou
Мақола20233 иқтибосABIPrecision sniper for solid tumors: CAR-NK cell therapy
Sisi Li, Jiajie Jing, Yueming Chen +6
Шарҳ мақола20253 иқтибосABIGPRC5D-Targeted CAR T Cells for Myeloma
Sham Mailankody, Sean M. Devlin, Jonathan Landa +35
Мақола20222 иқтибосABIOff-the-Shelf Chimeric Antigen Receptor T Cells
Norihiro Watanabe, Maksim Mamonkin
Шарҳ мақола20212 иқтибосABIEndowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing
Sumin Jo, Shipra Das, Alan F. Williams +19
Мақола20222 иқтибосABILiquid chromatography–tandem mass spectrometry for clinical diagnostics
Stefani N. Thomas, Deborah French, Paul J. Jannetto +2
Шарҳ мақола20222 иқтибосABI